Daiichi Sankyo Co. Ltd.’s (DSNKY.OB) Quizartinib, an oral tyrosine kinase inhibitor, which is under priority review by the FDA, awaits the decision on April 24, 2023.Quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, is proposed for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3-ITD positive.The drug is currently approved in Japan for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia, as detected by an approved test. Acute myeloid leukemia (AML) is one of the most common forms of leukemia in adults. Around 25% of newly identified cases of AML show the FLT3-ITD mutation, which is linked with an unfavorable prognosis, leading to a higher chance of relapse and shorter overall survival.DSNKY.OB closed Thursday’s trading at $35.89, up 2.17%.